Curis’s Emavusertib Trial Pause: What AML and MDS Investors Need to Know

Curis Inc. (CRIS) announced an update on their ongoing clinical study.

The study, titled “A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome,” tests Curis Inc.’s emavusertib in hard‑to‑treat blood cancers. It aims to find a safe dose, check early signs of benefit, and support future late‑stage trials in AML and high‑risk MDS.

The main treatment is emavusertib (CA‑4948), an oral tablet taken in 28‑day cycles to block a signaling pathway linked to cancer growth. Venetoclax was also tested in combination in one arm, but that part of the study is now closed, leaving emavusertib used alone as the key focus going forward.

This is an interventional Phase 1/2 trial with no random assignment, so everyone gets the study drug rather than a placebo or standard care arm. The trial is open‑label, meaning doctors and patients know what they receive, and the primary goal is treatment, not prevention or diagnosis.

The dose‑finding part follows a stepwise “3+3” style sequence, where small groups get rising doses until side effects become too strong, then expansion groups test the chosen dose in defined patient cohorts. While this structure is common in oncology, results can be slower and less predictable than in large randomized studies, which matters for timeline expectations.

The trial was first submitted on February 10, 2020, signaling Curis’s initial push to move emavusertib into AML and MDS. The most recent protocol update posted on March 17, 2026, marks a fresh data and design refresh that investors should see as a key milestone for assessing where the program stands.

No primary or final completion dates are listed yet, and the study is currently marked as “Suspended,” meaning enrollment or dosing is on hold. This pause can reflect safety reviews, protocol changes, or strategic shifts, and it typically raises questions about timing and probability of success for the program.

For CRIS, a suspended early‑stage trial in a core asset often pressures the stock in the near term as traders price in added clinical risk. Longer‑term investors will look for clarity on the reason for the hold, the path to resumption, and how this fits with Curis’s broader pipeline and cash runway.

In the AML and MDS space, Curis competes with larger players developing targeted drugs and combinations, including FLT3 and BCL‑2 inhibitors. Any signal that emavusertib can carve out a niche in mutation‑defined patients could support valuation, but delay or safety concerns may push investors to favor better‑derisked peers.

Overall, the latest update signals that the emavusertib study in AML and high‑risk MDS remains active from a regulatory listing standpoint but is temporarily suspended, and investors should monitor future disclosures and data releases, with further details available on the ClinicalTrials portal.

To learn more about CRIS’s potential, visit the Curis Inc. drug pipeline page.